Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study.

ABSTRACT:

Background

Growth differentiation factor 15 (GDF15) is a key regulator of body weight in animals by regulating food intake. Its receptor, glial cell-derived neurotrophic factor receptor alpha-like (GFRAL), was identified recently. Pre-clinical studies showed that it is a promising therapeutic target for cardiometabolic diseases and anorexia/cachexia. Although many pharmaceutical companies are developing drugs targeting GFRAL, whether the findings from animal studies can be extrapolated to man is unknown. Mendelian randomization (MR) is useful in investigating the relationship between risk factors and disease outcomes. We aimed to use a two-sample MR approach to evaluate the clinical usefulness of targeting GDF15 for cardiometabolic diseases.

Methods

Genetic instruments and s

SUBMITTER: Cheung CL 

PROVIDER: S-EPMC6442643 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature